It’s a seller’s world in biotech M&A, and Novartis CEO Vas Narasimhan has his check book out and pen ready

The Alcon spinoff is officially done today, debuting on the Swiss exchange with a market cap of $25 billion-plus, and Novartis CEO Vas Narasimhan is planning a long-running shopping spree in search of important new biotech products. And he’s been clearly focused on a late-stage strategy that has triggered a flashing red warning light at a world of potential rivals.